<SEC-DOCUMENT>0001104659-20-036830.txt : 20200320
<SEC-HEADER>0001104659-20-036830.hdr.sgml : 20200320
<ACCEPTANCE-DATETIME>20200320160647
ACCESSION NUMBER:		0001104659-20-036830
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200316
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200320
DATE AS OF CHANGE:		20200320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		20732048

	BUSINESS ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		2489609009

	MAIL ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2013290-1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>March 16, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ROCKWELL MEDICAL,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; font-size: 10pt; font-weight: bold; text-align: center">Delaware</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 33%; font-size: 10pt; font-weight: bold; text-align: center">000-23661</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; font-weight: bold; text-align: center">38-3317208</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">(State or other<BR> jurisdiction of<BR> incorporation)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">(Commission File<BR> Number)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">(IRS Employer<BR> Identification No.)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>411 Hackensack Avenue, Suite&nbsp;501,
Hackensack, New Jersey 07601</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(248) 960-9009</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt; text-indent: -13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of
the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">Title&nbsp;of&nbsp;each&nbsp;class</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">Trading&nbsp;Symbol(s)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">Name&nbsp;of&nbsp;each&nbsp;exchange&nbsp;on&nbsp;which&nbsp;registered</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">Common Stock, par value $.0001</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">RMTI</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Nasdaq Global Market</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule&nbsp;12b-2 of
the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. &nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><B><U>Item&nbsp;1.01</U></B></TD>
    <TD><B><U>Entry into a Material Definitive Agreement</U>. </B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Loan Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On March 16, 2020, the Rockwell Medical,
Inc. (the &#8220;Company&#8221;) and Rockwell Transportation, Inc., a wholly-owned subsidiary of the Company (&#8220;RTI&#8221;),
entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences Lending Fund I, LP,
a Delaware limited partnership (&#8220;Innovatus&#8221;), as collateral agent and the Lenders listed on Schedule 1.1 thereto, pursuant
to which Innovatus, as a Lender, has agreed to make certain term loans to the Company in the aggregate principal amount of up to
$35.0 million (the &#8220;Term Loans&#8221;). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company
will be eligible to draw on a second tranche of $5.0 million upon achievement of certain milestones, including the U.S. Food and
Drug Administration approval of the Company&#8217;s New Drug Application for I.V. Triferic. The Company will be eligible to draw
on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain
Triferic sales thresholds.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company is entitled to make interest-only
payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on the fifth anniversary
of the initial funding date, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii)
4.75%, plus 4.00%.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Loan Agreement is secured by all assets
of the Company and RTI. Proceeds will be used for working capital purposes. The Loan Agreement contains customary representations
and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing
twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020, or September 30, 2020 if the
Company draws the second tranche of $5.0 million.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with each funding of the
Term Loans, the Company is required to issue to Innovatus a warrant (the &#8220;Warrants&#8221;) to purchase a number of shares
of the Company&#8217;s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise
price, which will be based on the lower of (i) the volume weighted average closing price of the Company&#8217;s stock for the 5-trading
day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on
the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the
lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company&#8217;s stock for the 5-trading day
period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a
cashless basis, and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares
of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments
as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus,
exercisable for an aggregate of 477,273 shares of the Company&#8217;s common stock at an exercise price of $1.65 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The descriptions of the Loan Agreement
and the Warrants contained herein do not purport to be complete and are qualified in their entirety by reference to the complete
text of the Loan Agreement which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter
ending March 31, 2020 and the form of Warrant filed as Exhibit 4.1 attached hereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Baxter Amendment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On March 16, 2020, the Company and Baxter
Healthcare Corporation (&#8220;Baxter&#8221;) entered into a Second Amendment to Exclusive Distribution Agreement (the &#8220;Amendment&#8221;)
that revises the Exclusive Distribution Agreement dated October 2, 2014 between the Company and Baxter, as amended (the &#8220;Distribution
Agreement&#8221;) to, among other revisions, remove Baxter&#8217;s consent right over transactions granting a security interest
on the assets used to manufacture or commercialize the Company&#8217;s concentrates products and amend certain other terms of the
Distribution Agreement related to manufacturing and failure to supply, reimbursement for certain transportation costs, and conditions
for extension of the contract in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The description of the Amendment contained
herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment which
will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><B><U>Item&nbsp;2.03</U></B></TD>
    <TD><B><U>Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant</U>.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-indent: -58.5pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The information set forth in Item 1.01
above regarding the Loan Agreement is incorporated by reference into this Item 2.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-indent: -58.5pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><B><U>Item&nbsp;3.02</U></B></TD>
    <TD><B><U>Unregistered Sales of Equity Securities</U>. </B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-indent: -58.5pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">The information set forth in Item 1.01
above regarding the Warrants is incorporated by reference into this Item 3.02. The issuance of shares of the Company&#8217;s common
stock underlying the Warrants will be made in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities
Act of 1933, as amended, and Rule 506 of Regulation D thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><B><U>Item 8.01</U></B></TD><TD><B><U>Other Events</U>.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">On March 17, 2020, the Company issued a
press release announcing the Loan Agreement. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><B><U>Item&nbsp;9.01</U></B></TD>
    <TD><B><U>Financial Statements and Exhibits</U>. </B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;<I>Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT&nbsp;INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Exhibit&nbsp;No.</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Description</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; font-size: 10pt; text-align: left"><A HREF="tm2013290d1_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm2013290d1_ex4-1.htm" STYLE="-sec-extract: exhibit">Form of Warrant to Purchase Common Stock for Innovatus</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm2013290d1_ex99-1.htm">99.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2013290d1_ex99-1.htm">Press Release, dated March 17, 2020</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ROCKWELL MEDICAL,&nbsp;INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: March 20, 2020</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stuart Paul</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Stuart Paul</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm2013290d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<U>ACT</U>&rdquo;), OR THE SECURITIES LAWS OF
ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED (I)
UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR (II) WITHOUT AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY
TO THE COMPANY, THAT SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">FORM OF
WARRANT TO PURCHASE STOCK<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><SUP>1</SUP></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 25%">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 25%"><I>Company</I></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 50%">ROCKWELL MEDICAL, INC.</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><I>Number of Shares</I></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">[&nbsp;&nbsp;&nbsp;&nbsp;]</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><I>Type/Series of Stock</I></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">Common Stock</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><I>Warrant Price</I></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">$[&nbsp;&nbsp;&nbsp;&nbsp;]per share</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><I>Issue Date</I></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">[&nbsp;&nbsp;&nbsp;&nbsp;]</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><I>Expiration Date</I></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">[&nbsp;&nbsp;&nbsp;&nbsp;] (See also Section 5.1(b))</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><I>Credit Facility</I></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify">This Warrant to Purchase Stock (&ldquo;<U>Warrant</U>&rdquo;) is issued in connection with
    that certain Loan and Security Agreement, dated March 16, 2020, among Innovatus Life Sciences Lending Fund I, LP, as Lender
    and Collateral Agent, the Lenders from time to time party thereto, and the Company (as modified, amended and/or restated from
    time to time, the &ldquo;<U>Loan Agreement</U>&rdquo;).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS WARRANT CERTIFIES
THAT, for good and valuable consideration, <FONT STYLE="text-transform: uppercase">Innovatus Life Sciences Lending Fund I, LP
</FONT>(&ldquo;Innovatus&rdquo;), a Delaware limited partnership with an office located at 777 Third Avenue, 25th Floor, New York,
NY 10017 (together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise
hereof, &ldquo;<U>Holder</U>&rdquo;) is entitled to purchase the number of fully paid and non-assessable shares (the &ldquo;<U>Shares</U>&rdquo;)
of the above-stated Type/Series of Stock (the &ldquo;<U>Class</U>&rdquo;) of the above-named company (the &ldquo;<U>Company</U>&rdquo;)
at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the
provisions and upon the terms and conditions set forth in this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: none">SECTION
1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>EXERCISE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Method
of Exercise</U>. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to
the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached
hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2,
a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to
the Company for the aggregate Warrant Price for the Shares being purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1
</FONT>The Company acknowledges and agrees that the Warrant issued in connection with the Term A Loan under, and as defined in,
the Loan Agreement, will be at the lower of (i) the volume weighted average closing price of Rockwell&rsquo;s stock for the 5-trading
day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price
on the last trading day immediately preceding the execution of the Loan Agreement, and that, in the event the Company draws the
Term B Loan and/or the Term C Loan,&nbsp; each as defined therein, the Company shall issue the Holder additional Warrants to purchase
shares of the Company&rsquo;s common stock, equal to 3.50% of the funded amount of such Term B and Term C Loans, respectively,
at the lower of (i) Warrant Price for this Warrant or (ii) the volume weighted average closing price of Rockwell&rsquo;s stock
for the 5-trading day period ending on the last trading day immediately preceding the funding of the Term B Loan or Term C Loan,
as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner
as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive
Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company
shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify; text-indent: 0">X = Y(A-B)/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">where:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font-family: Times New Roman, Times, Serif; width: 1.6in"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in">X =</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify">the
                                         number of Shares to be issued to the Holder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font-family: Times New Roman, Times, Serif; width: 1.6in"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in">Y =</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify">the number of Shares with respect
                                         to which this Warrant is being exercised (inclusive of the Shares surrendered to the
                                         Company in payment of the aggregate Warrant Price);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font-family: Times New Roman, Times, Serif; width: 1.6in"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in">A =</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify">the
                                         Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font-family: Times New Roman, Times, Serif; width: 1.6in"></TD><TD STYLE="font-family: Times New Roman, Times, Serif; width: 0.5in">B =</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify">the
                                         Warrant Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fair Market Value</U>. If the Company&rsquo;s common stock is then traded or quoted on a nationally recognized securities
exchange, inter-dealer quotation system or over-the-counter market (a &ldquo;<U>Trading Market</U>&rdquo;) and the Class is common
stock, the fair market value of a Share shall be the closing price or last sale price of a share of common stock reported for
the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the
Company. If the Company&rsquo;s common stock is not traded or quoted on a Trading Market, the Board of Directors of the Company
shall determine the fair market value of a Share in its reasonable good faith judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Certificate and New Warrant</U>. Promptly after Holder exercises this Warrant in the manner set forth in
Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such
exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Shares
not so acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Replacement of Warrant</U>. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably
satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company
for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant
of like tenor and amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Treatment of Warrant Upon Acquisition of Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Acquisition</U>.
For the purpose of this Warrant, &ldquo;<U>Acquisition</U>&rdquo; means any transaction or series of related transactions
involving: (i) the sale, lease, exclusive license or other disposition of all or substantially all of the assets of the
Company; (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or
consolidation effected exclusively to change the Company&rsquo;s domicile), or any other corporate reorganization, in which
the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization,
own less than a majority of the Company&rsquo;s (or the surviving or successor entity&rsquo;s) outstanding voting power
immediately after such merger, consolidation or reorganization; or (iii) any sale or other transfer by the stockholders of
the Company of shares representing a majority of the Company&rsquo;s then-total outstanding combined voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Treatment of Warrant at Acquisition</U>. In the event of an Acquisition in which the consideration to be received by
the Company&rsquo;s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable
Securities (a &ldquo;<U>Cash/Public Acquisition</U>&rdquo;), either (i) Holder shall exercise this Warrant pursuant to Section
1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition
or (ii) if Holder elects not to exercise the Warrant, this Warrant will expire immediately prior to the consummation of such Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall provide Holder with written notice of its request relating to the Cash/Public Acquisition (together with
such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated
Cash/Public Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) Business Days prior
to the closing of the proposed Cash/Public Acquisition. Notwithstanding the foregoing, if, immediately prior to the Cash/Public
Acquisition, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance
with Section 1.3 above would be greater than the Warrant Price in effect on such date, then this Warrant shall automatically be
deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which
it shall not previously have been exercised, and the Company shall promptly notify the Holder of the number of Shares (or such
other securities) issued upon such exercise to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor
entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities
and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant
as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time
in accordance with the provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As used in this Warrant, &ldquo;<U>Marketable Securities</U>&rdquo; means securities meeting all of the following requirements:
(i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange
Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), and is then current in its filing of all required reports and
other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that
would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing
thereof is then traded in Trading Market; and (iii) Holder would be able to publicly re-sell, within six (6) months following
the closing of such Acquisition, all of the issuer&rsquo;s shares and/or other securities that would be received by Holder in
such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of such Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: none">SECTION
2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>ADJUSTMENTS TO THE SHARES AND WARRANT PRICE</U>.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends, Splits, Etc</U>. If the Company declares or pays a dividend or distribution on the outstanding shares
of the Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for
each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property
which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If
the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the
number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased.
If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of
shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reclassification, Exchange, Combinations or Substitution</U>. Upon any event whereby all of the outstanding shares of
the Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different
class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class
and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation
of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant.
The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions,
replacements or other similar events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intentionally Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intentionally Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Share</U>. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares
to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the
Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying
the fractional interest by (a) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less
(b) the then-effective Warrant Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice/Certificate as to Adjustments</U>. Upon each adjustment of the Warrant Price, Class and/or number of Shares,
the Company, at the Company&rsquo;s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments
to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written
request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment
and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: none">SECTION
3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 </FONT></FONT><U>REPRESENTATIONS
AND COVENANTS OF THE COMPANY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. The Company represents and warrants to, and agrees with, the Holder as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[The initial Warrant Price referenced on the first page of this Warrant is not greater than the lower of (i) the volume
weighted average closing price of Rockwell&rsquo;s stock for the 5-trading day period ending on the last trading day immediately
preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution
of the Loan Agreement.]<FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT> [The initial Warrant Price referenced on the first
page of this Warrant is not greater than the lower of (i) Warrant Price for the Warrant issued by the Company to the Holder on
March 16, 2020 or (ii) the volume weighted average closing price of Rockwell&rsquo;s stock for the 5-trading day period ending
on the last trading day immediately preceding the Issue Date.]<FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon conversion
of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens
and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.
The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital
stock such number of shares of the Class, common stock and other securities as will be sufficient to permit the exercise in full
of this Warrant and the conversion of the Shares into common stock or such other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company&rsquo;s capitalization table attached hereto as Schedule 1 is true and complete, in all material respects,
as of the Issue Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice of Certain Events</U>. If the Company proposes at any time to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property,
stock, or other securities and whether or not a regular cash dividend;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>offer for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of
any class or series of the Company&rsquo;s stock (other than pursuant to contractual pre-emptive rights);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding
shares of the Class; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>effect an Acquisition or to liquidate, dissolve or wind up;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, in connection with each such event,
the Company shall give Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(1) at least
seven (7) Business Days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription
rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto) or for determining
rights to vote, if any, in respect of the matters referred to in (a) and (b) above; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(2) in
the case of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the date
when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be
entitled to exchange their shares for the securities or other property deliverable upon the occurrence of such event).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
be included for the Term A Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
be included for the Term B Warrants and Term C Warrants, as applicable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is made to Section 1.6(c) whereby
this Warrant will be deemed to be exercised pursuant to Section 1.2 hereof if the Company does not give written notice to Holder
of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder that is
reasonably necessary to enable Holder to comply with Holder&rsquo;s accounting or reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights</U>. In the event that the Company files a resale registration statement at any time after the Issue
Date, the Company will use reasonable efforts to include the securities to be acquired upon exercise of this Warrant in such resale
registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: none">SECTION
4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>REPRESENTATIONS,
WARRANTIES OF THE HOLDER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Holder represents
and warrants to the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Purchase for Own Account.</U> This Warrant and the securities to be acquired upon exercise of this Warrant by Holder
are being acquired for investment for Holder&rsquo;s account, not as a nominee or agent, and not with a view to the public resale
or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of
acquiring this Warrant or the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Information.</U> Holder is aware of the Company&rsquo;s business affairs and financial condition and has
received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision
with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions
and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities
and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable
effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Investment Experience.</U> Holder understands that the purchase of this Warrant and its underlying securities involves
substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that
Holder can bear the economic risk of such Holder&rsquo;s investment in this Warrant and its underlying securities and has such
knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment
in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and
certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character,
business acumen and financial circumstances of such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accredited Investor Status.</U> Holder is an &ldquo;accredited investor&rdquo; within the meaning of Regulation D promulgated
under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>The
Act.</U> Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the
Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature
of the Holder&rsquo;s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon
any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable
state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware
of the provisions of Rule 144 promulgated under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Voting Rights</U>. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: none">SECTION
5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>MISCELLANEOUS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term and Automatic Conversion Upon Expiration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time
and from time to time on or before 6:00 P.M., Eastern time, on the Expiration Date and shall be void thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Automatic Cashless Exercise upon Expiration</U>. In the event that, upon the Expiration Date, the fair market value
of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater
than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised
pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised,
and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued
upon such exercise to Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Legends</U>. The Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any)
shall be imprinted with a legend in substantially the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">THE SHARES EVIDENCED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<U>ACT</U>&rdquo;), OR THE SECURITIES LAWS OF
ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO <FONT STYLE="text-transform: uppercase">Innovatus
Life Sciences Lending Fund I, LP</FONT> DATED MARCH 16, 2020, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED (I) UNLESS
AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR (II) WITHOUT AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY
TO THE ISSUER, THAT SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Securities Laws on Transfer</U>. This Warrant and the Shares issuable upon exercise of this Warrant
(and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned
in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee
(including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to
the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if
the transfer is to an affiliate of Holder. Additionally, the Company shall also not require an opinion of counsel if there is
no material question as to the availability of Rule 144 promulgated under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Procedure.</U> Subject to the provisions of Section 5.3 and upon providing the Company with written notice,
Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable
directly or indirectly, upon conversion of the Shares, if any) to any transferee, <U>provided</U>, <U>however</U>, in connection
with any such transfer, Holder will give the Company notice of the portion of the Warrant being transferred with the name, address
and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the
transferee(s) (and Holder if applicable); and <U>provided further</U>, that any subsequent transferee shall agree in writing with
the Company to be bound by all of the terms and conditions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be
deemed delivered and effective (i) when given personally, (ii) on the third (3<SUP>rd</SUP>) Business Day after being mailed by
first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail
and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable
overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder,
as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section
5.5. All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection
with a transfer or otherwise:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.6in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">INNOVATUS LIFE SCIENCES LENDING FUND I, LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.6in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">777 Third Avenue, 25th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.6in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.6in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Attention: Claes Ekstrom</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notice to the Company
shall be addressed as follows until Holder receives notice of a change in address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin-left: 1.6in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">ROCKWELL MEDICAL, INC.</P>

<P STYLE="margin-left: 1.6in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">411 Hackensack Avenue, Suite 501<BR>
Hackensack, NJ 07601</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.6in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-left: 1.6in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Attn: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.6in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-left: 1.6in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">With a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.6in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-left: 1.6in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Gibson, Dunn &amp; Crutcher LLP</P>

<P STYLE="margin-left: 1.6in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">555 Mission Street, Suite 3000</P>

<P STYLE="margin-left: 1.6in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">San Francisco, CA 94105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver</U>. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in
a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against
which enforcement of such change, waiver, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Attorneys&rsquo; Fees</U>. In the event of any dispute between the parties concerning the terms and provisions of this
Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute,
including reasonable attorneys&rsquo; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts; Facsimile/Electronic Signatures</U>. This Warrant may be executed in counterparts, all of which together
shall constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the
same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Warrant shall be governed by and construed in accordance with the laws of the State of New York,
without giving effect to its principles regarding conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect
the meaning of any provision of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Business Days</U>. &ldquo;<U>Business Day</U>&rdquo; is any day that is not a Saturday, Sunday or a day on which banks
in New York, New York are closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective as of
the Issue Date written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;COMPANY&rdquo;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ROCKWELL MEDICAL, INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 1pt; font-size: 10pt">(Print)</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HOLDER&rdquo;</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>INNOVATUS LIFE SCIENCES LENDING FUND I, LP</B></FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; font-size: 10pt; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; font-size: 10pt; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 1pt; font-size: 10pt">(Print)</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">APPENDIX
1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>NOTICE
OF EXERCISE</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned Holder hereby exercises its right purchase ___________ shares of the Common Stock of ROCKWELL MEDICAL, INC. (the &ldquo;<U>Company</U>&rdquo;)
in accordance with the attached Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-family: Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">check in the amount of $________ payable
    to order of the Company enclosed herewith</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">Wire transfer of immediately available funds to
    the Company&rsquo;s account</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">Cashless Exercise pursuant to Section 1.2 of the
    Warrant</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">Other [Describe] __________________________________________</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue a certificate or certificates representing the Shares in the name specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1.1in">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">___________________________________________</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Name</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">___________________________________________</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">___________________________________________</TD></TR>
<TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">(Address)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section
4 of the Warrant to Purchase Stock as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HOLDER:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-top: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 3pt; font-size: 10pt; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 3pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 3pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Date):</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 3pt; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Appendix
1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SCHEDULE
1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Company Capitalization Table</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">The number of shares of common stock outstanding&nbsp;as of
November&nbsp;12, 2019 was 63,955,893 (as set forth in the Company&rsquo;s quarterly report on Form 10-Q filed with the SEC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Schedule 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2013290d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="tm2013290d1_ex99-1img01.jpg" ALT=""></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
IMMEDIATE RELEASE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rockwell
Medical, Inc. Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif">First $22.5 million tranche funded at closing -</FONT></P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WIXOM,
Mich., </B>March 17, 2020 &ndash; Rockwell Medical, Inc. (NASDAQ:RMTI) (&ldquo;Rockwell Medical&rdquo; or the &ldquo;Company&rdquo;),
a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world,
today announced that it has entered into a debt financing agreement with an affiliate of Innovatus Capital Partners, LLC (&quot;Innovatus&quot;)
to provide the Company with up to $35.0 million in term loans.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&quot;We
are pleased to partner with Innovatus on this transaction,&quot; said Stuart Paul, President and Chief Executive Officer of Rockwell
Medical. &ldquo;This financing will provide flexibility as we continue our mission to advance our novel therapeutic, Triferic,
and to transform the way anemia is managed around the world,&rdquo; concluded Mr. Paul.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 16, 2020, the Company entered into a loan and security agreement (the &quot;Loan Agreement&quot;) with Innovatus pursuant
to which Innovatus has agreed to make certain term loans in the aggregate principal amount of up to $35.0 million, with the funding
of the first $22.5 million tranche funded at closing. The Company will be eligible to draw on a second tranche of $5,000,000 upon
achievement of certain milestones, including the U.S. Food and Drug Administration approval of the Company&rsquo;s NDA for I.V.
Triferic. The Company will be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones,
including the achievement of certain Triferic sales thresholds. The Company is entitled to make interest-only payments for thirty
months, or up to thirty-six months if certain conditions are met. The loans will mature on the fifth anniversary of the initial
funding date. The Loan Agreement includes customary warrant coverage and is secured by all of the Company&rsquo;s assets. Proceeds
will be used for working capital purposes.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;We
are delighted to partner with Rockwell Medical in its pursuit of transforming anemia management for dialysis patients,&rdquo;&nbsp;stated
Claes Ekstrom, Managing Director at Innovatus.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
transaction is the culmination of a multi-step financing process that Rockwell Medical initiated during the fourth quarter of
2019. At the urging of shareholders, the Company prioritized non-dilutive financing options as part of the process, and the Company
consummated the public offering of common stock in February 2020 to help facilitate this non-dilutive financing.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cantor
Fitzgerald &amp; Co acted as sole financial advisor to Rockwell Medical on this transaction.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
details regarding the Company's financing are included in the Company&rsquo;s Current Report on Form 8-K which is expected to
be filed with the Securities and Exchange Commission within four business days of the date of this press release.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>About
Rockwell Medical</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rockwell
Medical is a biopharmaceutical company dedicated to transforming anemia management in a wide variety of therapeutic areas and
across the globe, improving the lives of very sick patients. The Company&rsquo;s initial focus is the treatment of anemia in end-stage
renal disease (ESRD). Rockwell Medical's exclusive renal drug therapy, Triferic (ferric pyrophosphate citrate), is the only FDA-approved
therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. The Company has developed multiple
formulations of Triferic (1) FDA-approved Dialysate Triferic, and (2) I.V. Triferic, for which the Company filed a New Drug Application
in May 2019. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis
concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Innovatus
Capital Partners, LLC</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Innovatus
Capital Partners, LLC, is an independent adviser and portfolio management firm with approximately $1.65B in assets under management.
Innovatus adheres to an investment strategy that identifies disruptive and growth opportunities across multiple asset categories
with a unifying theme of capital preservation, income generation, and upside optionality. The firm has a dedicated team of life
sciences investment professionals with deep experience in healthcare, including life sciences. Innovatus and its principals have
significant experience providing debt financing to medical device, diagnostics, and biotechnology companies that address unmet
medical needs, improve patient outcomes, and reduce overall healthcare expenditures. Further information can be found at <U>www.innovatuscp.com</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>About
Triferic</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Triferic
is the only FDA-approved therapy in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate
during each dialysis treatment. Triferic has a unique and differentiated mechanism of action which has the potential to benefit
patients and health care economics. Triferic represents a potential innovative medical advancement in hemodialysis patient iron
management&ndash; with the potential to become the future standard of care.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Triferic
delivers approximately 5-7 mg iron with every hemodialysis treatment to the bone marrow and maintains hemoglobin without increasing
iron stores (ferritin). Triferic donates iron immediately and completely to transferrin (carrier of iron in the body) upon entry
into the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin
(stored iron and inflammation) and no reports of anaphylaxis in over 1,000,000 patient administrations, addressing a significant
medical need in overcoming Functional Iron Deficiency (FID) in ESRD patients.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Important
Safety Information</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Serious
hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been
reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension,
loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis
until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity
reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving Triferic in two randomized clinical
trials.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Iron
status should be determined on pre-dialysis blood samples. Post dialysis serum iron parameters may overestimate serum iron and
transferrin saturation.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
most common adverse reactions (&#8805;3% and at least 1% greater than placebo) in controlled clinical studies include: procedural
hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain in extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%),
back pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%), asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula
thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Forward
Looking Statements </B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certain
statements in this press release may constitute &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities
laws, including, but not limited to, Rockwell Medical&rsquo;s expectations regarding the consummation of the offering, the terms
of the offering, and the satisfaction of customary closing conditions with respect to the offering and the anticipated use of
the net proceeds of the offering. Words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;forecast,&rdquo; &ldquo;project,&rdquo; &ldquo;intend&rdquo;
or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While
Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those
set forth in Rockwell Medical&rsquo;s SEC filings), many of which are beyond our control and subject to change. Actual results
could be materially different. Risks and uncertainties include: the timing and regulatory approval process for our NDA filing
for I.V. Triferic as filed with the FDA: the timing and receipt of the loan amounts from Innovatus; Rockwell Medical&rsquo;s ability
to achieve certain milestones under the Loan Agreement; and the anticipated use of proceeds under the Loan Agreement, as well
as those risks more fully discussed in Rockwell Medical&rsquo;s SEC filings. Accordingly, you should not place undue reliance
on these forward-looking statements. Rockwell Medical expressly disclaims any obligation to update or alter any statements whether
as a result of new information, future events or otherwise, except as required by law.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Triferic&reg;
is a registered trademark of Rockwell Medical, Inc.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Contact<BR>
</B>Investor Relations:<BR>
Lisa M. Wilson, In-Site Communications, Inc.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">T:
212-452-2793<BR>
E: <U>lwilson@insitecony.com</U></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Source:
Rockwell Medical, Inc.</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2013290d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2013290d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  _ 4 # 2(  A$! Q$!_\0
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MP:/=:KH\UYXVT#3[EK6+7=+U?3P;C3[RXM9'>R>1(Y6:&2*3$@_G'_X-R/\
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MW$NXU9B2958H4+0LT; &.0##QNDBG!)5XW5U?:Z,"%(_)WX6_#'XF_L!>-/
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M;2K5+W7=?UO4KA++0?"WAS399H(M0U_7+Z>&"QMVGA4*WFRS) DCK?\ V/\
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AIN<F[/5JA&M23I2A3E!U9RYT[-*3NFXO5M[63LK6L?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
